Core Insights - Microbot Medical Inc. (MBOT) has received a new U.S. patent that enhances the LIBERTY Endovascular Robotic System's applications, allowing for interchangeable tool-receiver units, thus broadening its use in endovascular procedures [1][8] - The new intellectual property (IP) is expected to increase the addressable market for the company from approximately 2.5 million to over six million annual endovascular procedures in the U.S., significantly expanding its market potential [2][8] - Following the patent announcement, MBOT's shares rose by 7.1%, with a year-to-date increase of 195.5%, contrasting with a 7% decline in the industry [3][7] Company Developments - The newly granted patent strengthens Microbot's long-term growth prospects by broadening the LIBERTY system's potential applications, enhancing its competitive differentiation and positioning for future partnerships and revenue opportunities once FDA clearance is obtained [4][8] - MBOT currently has a market capitalization of $140.7 million and projects an earnings growth of 56.2% for the current year [5] Product Overview - The LIBERTY system is designed as a single-use, fully disposable robotic platform for endovascular procedures, aimed at simplifying workflow and reducing risks associated with reprocessing [9][10] - Its modular architecture allows for configuration across various clinical applications, potentially increasing its relevance in a wider range of procedures than initially targeted [9][10]

Core Insights - The company has received a new patent for its LIBERTY Endovascular Robotic System, bringing its total to 12 granted patents globally and 57 pending applications, which enhances its intellectual property portfolio [1][2] - The new patent allows for modular capabilities in the robotic system, potentially expanding its application to a wider range of endovascular procedures, thereby increasing the Total Addressable Market (TAM) [1][2] - The company aims to address over 6 million annual endovascular procedures in the U.S., significantly higher than the current estimate of 2.5 million procedures [2][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [4] - The company has developed the first single-use, fully disposable endovascular robotic system, which aims to remove traditional barriers to accessing advanced robotic systems [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 175 Derby St., Bld. 27 Hingham, MA 02043 (Address of principal executive of ices) (781) 875-3605 (Registrant's T ...

Core Insights - Microbot Medical Inc. has received a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority to enhance its manufacturing capabilities for the LIBERTY® Endovascular Robotic System, pending FDA marketing clearance [1][2][3] Group 1: Company Developments - The grant is expected to strengthen the company's balance sheet and operational readiness as it awaits FDA's decision on marketing clearance [3] - The Israel Innovation Authority recognized the company's recent achievements, the target market's size, the competitive advantages of a single-use robot, and the expected benefits to healthcare systems [2] - The LIBERTY® System is an investigational device currently pending FDA 510(k) clearance and is not available for sale in the U.S. [3][4] Group 2: Market Positioning - Microbot Medical aims to redefine endovascular robotics and improve care quality for patients globally with its single-use, fully disposable robotic system [4] - The company believes the grant validates its technology and reflects the IIA's confidence in its ability to scale manufacturing and meet business objectives [2][3]

Company Continues to Strengthen Organizational Infrastructure with Success-Driven Medical Device Veteran HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals. She will report directly ...

Core Insights - Microbot Medical Inc. is participating in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, highlighting the growth and innovation in the endovascular robotics field driven by market demand [1][3] - The session will feature discussions on emerging technologies in the peripheral vascular, neurovascular, and cardiovascular spaces, with a focus on educating the medical community about the LIBERTY Endovascular Robotic System [2][3] - The SRS aims to foster education and collaboration in robotic surgery, providing opportunities for multi-centric studies and training for young professionals in the field [4] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [6] - The company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to remove barriers to accessing advanced robotic systems [6] - The LIBERTY system is currently pending FDA 510(k) clearance and is not available for sale in the U.S. as the company strengthens its sales and marketing infrastructure for its launch [5]

Core Insights - Microbot Medical Inc. has been added to the Russell Microcap Index, effective June 30, 2025, enhancing its visibility in the market [1][2] - The inclusion reflects the company's strong execution and momentum, particularly in relation to its LIBERTY Endovascular Robotic System and ongoing FDA interactions [2] - The Russell US Indexes reconstitution captures the 4,000 largest US stocks, and membership in the Russell Microcap Index ensures automatic inclusion in relevant growth and value style indexes [2][3] Company Overview - Microbot Medical is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally [4] - The company has developed the world's first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems [4] Market Context - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [3]

Core Insights - Microbot Medical Inc. has been granted a critical patent in China for its LIBERTY Endovascular Robotic System, marking a significant step in its global intellectual property expansion strategy [1] - The company currently holds nine patents globally and has 59 pending patent applications, which helps maintain a competitive advantage and protect the unique capabilities of the LIBERTY System [2] - Preparations for the anticipated U.S. launch of the LIBERTY System are underway, with regulatory, operational, and commercial activities accelerating [3] - The company aims to impact both developed and emerging markets, with an estimated 2 million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China [4] - Microbot Medical is focused on redefining endovascular robotics and improving patient care through its innovative, single-use, fully disposable robotic system [5]

Core Viewpoint - Microbot Medical Inc. (MBOT) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2]. - The Zacks rating upgrade for Microbot Medical signifies an optimistic earnings outlook, likely leading to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for fair value calculations [5]. - For Microbot Medical, the recent increase in earnings estimates suggests an improvement in the company's underlying business, which should positively influence stock performance [6]. Performance of Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Microbot Medical to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Recent Earnings Estimate Trends - For the fiscal year ending December 2025, Microbot Medical is expected to earn -$0.32 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 38.5% over the past three months [9].

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]